How has been the historical performance of Aspira Pathlab?

Answer:The historical performance of Aspira Pathlab shows significant improvement from March 2024 to March 2025.

Breakdown:
Aspira Pathlab's net sales increased from 13.20 Cr in March 2024 to 22.00 Cr in March 2025, reflecting a strong growth in total operating income, which also rose to 22.00 Cr from 13.20 Cr. The total expenditure, excluding depreciation, increased to 18.83 Cr from 14.76 Cr, primarily driven by higher raw material costs and employee expenses. However, the operating profit (PBDIT) turned positive, reaching 3.56 Cr compared to a loss of 1.14 Cr in the previous year. Consequently, profit before tax improved to 2.07 Cr from a loss of 2.67 Cr, leading to a net profit of 2.02 Cr, a notable recovery from the previous year's loss. The earnings per share (EPS) also reflected this positive trend, increasing to 1.96 from a loss of 2.59. The operating profit margin improved significantly to 14.41% from -11.82%, while the profit after tax margin turned positive at 9.18% compared to -20.23%. On the balance sheet, total assets grew to 17.46 Cr from 14.71 Cr, with total liabilities also increasing to 17.46 Cr from 14.71 Cr, indicating a balanced growth. Cash flow from operating activities remained stable at 1.00 Cr, with closing cash and cash equivalents rising to 1.00 Cr from zero, showcasing improved liquidity. Overall, Aspira Pathlab demonstrated a robust recovery and growth trajectory in its financial performance over the year.